Open an Account
search icon
3
NOTIFICATIONS
Best Algo trading app in India
Bigul

Tatva Chintan Pharma Chem Ltd - 543321 - Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - Intimation

 Dear Sir/Madam, Sub: Intimation of Schedule of Analyst/ Institutional Investor meeting. Pursuant to Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended, we hereby submit schedule of analyst/institutional investors meeting that the Company would be participating: Date Particulars Type Mode 01 November 2021 Axis Mutual Fund One on One Virtual Please note that the above shall be subject to changes, if any. Kindly take the above disclosure on your records.
31-10-2021
Bigul

Tatva Chintan Pharma Chem Ltd - 543321 - Investor Deck

 Please find enclosed herewith, 'INVESTOR DECK' which contain general and financial information about the company. This information is being submitted for general purpose only and not under any statutory requirements. Kindly take note of the same. The same will also be available on the Company''s website, ''www.tatvachintan.com''. This is for your information and records.
29-10-2021
Bigul

Tatva Chintan Pharma Chem Ltd - 543321 - Announcement under Regulation 30 (LODR)-Earnings Call Transcript

 Pursuant to Regulation 30 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 as amended, please find enclosed herewith the transcript of the earnings call held on 25 October 2021 post announcement of financial results of the Company for the quarter and half year ended 30 September 2021. The Transcript has been uploaded on the Company's website www.tatvachintan.com. This is for your information and records.
29-10-2021
Bigul

Tatva Chintan Pharma Chem Ltd - 543321 - Announcement under Regulation 30 (LODR)-Monitoring Agency Report

 Pursuant to Regulation 32(6) of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 as amended, please find enclosed a copy of the Monitoring agency report of the Company for the quarter ended 30 September 2021, issued by ICICI Bank Limited, appointed to monitor the utilization of proceeds of an Initial Public Offering ('IPO') of the Company. Request you to please take the above on record.
28-10-2021
Bigul

Tatva Chintan Pharma Chem Ltd - 543321 - Statement Of Deviation / Variation In Utilization Of Funds Raised Through IPO

 Pursuant to Regulation 32(1) of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 as amended, please find enclosed herewith statement of deviation(s) or variation(s) in utilization of funds raised through Initial Public Offering (IPO) for the quarter ended 30 September 2021 in the prescribed format. The same will be filed in XBRL mode separately. We confirm that, as at 30 September 2021, there has not been any deviation(s) or variation(s) in the utilization of net proceeds of IPO as mentioned in the objects stated in the Prospectus dated 22 July 2021. Monitoring agency report issued in this regard is being separately filed with the exchange. Kindly take the above information on your record.
27-10-2021
Bigul

Tatva Chintan Pharma Chem Ltd - 543321 - Statement Of Deviation / Variation In Utilization Of Funds Raised Through IPO

 Pursuant to Regulation 32(1) of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 as amended, please find enclosed herewith statement of deviation(s) or variation(s) in utilization of funds raised through Initial Public Offering (IPO) for the quarter ended 30 September 2021 in the prescribed format. The same will be filed in XBRL mode separately. We confirm that, as at 30 September 2021, there has not been any deviation(s) or variation(s) in the utilization of net proceeds of IPO as mentioned in the objects stated in the Prospectus dated 22 July 2021. Monitoring agency report issued in this regard is being separately filed with the exchange. Kindly take the above information on your record.
27-10-2021
Bigul

Q2FY22 Quarterly Result Announced for Tatva Chintan Pharma Chem Ltd.

 Highlights: Revenue from Operations for the quarter was Rs 1,236.15 million higher by 106% EBITDA for the quarter was Rs 386.98 million higher by 365% EBIDTA Margin for the quarter was at 31.31% higher by 1,746 bps Net Profit for the quarter was Rs 324.12 million higher by 811% Net Profit Margin for the quarter was at 25.64% higher by 1990 bps Basic and Diluted EPS for the quarter was Rs 15.02 per share, increased by 749% Results at Glance (Y-O-Y – 1H FY22 COMPARED WITH 1H FY21) Revenue from Operations for the half year was Rs 2,304.47 million higher by 107% EBITDA for the half year was Rs 662.96 million higher by 242% EBIDTA Margin for the half year was at 28.77% higher by 1,138 bps Net Profit for the half year was Rs 555.58 million higher by 441% Net Profit Margin for the half year was at 23.64% higher by 1,466 bps Basic and Diluted EPS for the half year was Rs 26.7 per share, increased by 422% Commenting on the Q2 & H1 performance Mr. Chintan Shah, Managing Director, said, as we have announced our results just before Diwali; I take this opportunity to wish each one of you a very Happy Diwali and Prosperous New year, let us hope we all have a wonderful, successful & most importantly a healthy year ahead. I am pleased to inform you that we have reported a historically record-breaking performance in 2QFY22; we are very well on our way of being recognized as a niche player in the speciality chemical space with our focus on manufacturing Phase Transfer Catalyst, Structure Directing Agents, Electrolyte Salts, Pharma & Agrochemical Intermediates and Speciality Chemicals. We have a clear focus on adopting green chemistry processes supported by our state-of-the-art research and development facility and manufacturing plants. With the wide range of applications of our products, TCPCL can cater to customers across wide spectrum of chemical Industries which ensures a sustainable business model. Diversified product portfolio has helped accelerate our growth. We recently got listed on NSE/BSE on 29 July 2021, out of our net IPO proceeds of Rs 2,072.81 million, Rs 396.85 million have been utilized as on 30 September 2021. The capacity expansion is underway at our Dahej SEZ manufacturing plant and at our R&D; facility at Vadodara. Result PDF
26-10-2021
Bigul

Tatva Chintan Pharma Chem Ltd - 543321 - Announcement under Regulation 30 (LODR)-Press Release / Media Release

 Pursuant to Regulation 30 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 as amended, please find enclosed a copy of the Press Release on the financial results of the Company for the quarter and half year ended 30 September 2021. The same will also be available on the Company''s website, ''www.tatvachintan.com''. This is for your information and records.
26-10-2021

Earnings Call for Q2FY22 of Tatva Chintan Pharma Chem

 Conference Call with Tatva Chintan Pharma Chem Management and Analysts on Q2FY22 Performance and Outlook. Listen to the full earnings transcript.
26-10-2021
Bigul

Tatva Chintan Pharma Chem Ltd - 543321 - Announcement under Regulation 30 (LODR)-Newspaper Publication

 Pursuant to regulation 30 and 47 of the Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations.2015, as amended, we are enclosing herewith copies newspaper publication of extract of unaudited financial results of the Company for the quarter ended on 30 September 2021, published in Financial Express (English edition) and Vadodara Samachar (Gujarati edition) on 24 October 2021. Kindly take the same on record and disseminate to the public at large
25-10-2021
Next Page
Close

Let's Open Free Demat Account